% | $
Quotes you view appear here for quick access.


you are viewing a single comment's thread.

view the rest of the posts
  • ihate_brokers ihate_brokers Feb 11, 2000 12:16 AM Flag

    Anyone else receive...

    Draxis Health Starts Phase III Fibrimage
    MISSISSAUGA, Ont. -- Draxis Health Inc. (DRAX)
    said its Draximage Inc. radiopharmaceutical subsidiary
    has started Phase III
    clinical trials in Canada
    for Fibrimage, a diagnostic tool for deep vein
    thrombosis, or DVT.
    In a news release, the drug company
    said the trial should involve 130 patients and be
    completed by the end of the year.
    DVTs are blood clots
    that form in the lower limbs and can lead to a
    pulmonary embolism, or a blockage of blood flow to the
    lungs, a
    condition that kills about 200,000 people a
    year in the U.S., it said.
    It said Fibrimage is
    based on Fibrin Binding Domain, a recombinant
    polypeptide developed by Bio-Technology General Corp.

    (BTGC) and licensed to Draximage on an exclusive,
    worldwide basis

    SortNewest  |  Oldest  |  Most Replied Expand all replies